Clinical trial NCT02689986 - References

Autoimmune Hemolytic Anemia — Bendamustine and Rituximab Combination Therapy for Cold Agglutinin Disease

Citation(s)

•   Berentsen S, Beiske K, Tjønnfjord GE
  Primary chronic cold agglutinin disease: an update on pathogenesis, clinical features and therapy. Hematology. 2007 Oct;12(5):361-70. Review.
•   Berentsen S, Randen U, Vågan AM, Hjorth-Hansen H, Vik A, Dalgaard J, Jacobsen EM, Thoresen AS, Beiske K, Tjønnfjord GE
  High response rate and durable remissions following fludarabine and rituximab combination therapy for chronic cold agglutinin disease. Blood. 2010 Oct 28;116(17):3180-4. doi: 10.1182/blood-2010-06-288647.
•   Berentsen S, Tjønnfjord GE, Shammas FV, Bergheim J, Hammerstrøm J, Langholm R, Ulvestad E
  No response to cladribine in five patients with chronic cold agglutinin disease. Eur J Haematol. 2000 Jul;65(1):88-90.
•   Berentsen S, Tjønnfjord GE
  Diagnosis and treatment of cold agglutinin mediated autoimmune hemolytic anemia. Blood Rev. 2012 May;26(3):107-15. doi: 10.1016/j.blre.2012.01.002. Review.
•   Berentsen S, Ulvestad E, Gjertsen BT, Hjorth-Hansen H, Langholm R, Knutsen H, Ghanima W, Shammas FV, Tjønnfjord GE
  Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients. Blood. 2004 Apr 15;103(8):2925-8.
•   Berentsen S, Ulvestad E, Langholm R, Beiske K, Hjorth-Hansen H, Ghanima W, Sørbø JH, Tjønnfjord GE
  Primary chronic cold agglutinin disease: a population based clinical study of 86 patients. Haematologica. 2006 Apr;91(4):460-6.
•   Berentsen S, Ulvestad E, Tjønnfjord GE
  B-lymphocytes as targets for therapy in chronic cold agglutinin disease. Cardiovasc Hematol Disord Drug Targets. 2007 Sep;7(3):219-27. Review.
•   Berentsen S
  How I manage cold agglutinin disease. Br J Haematol. 2011 May;153(3):309-17. doi: 10.1111/j.1365-2141.2011.08643.x. Review.
•   Gueli A, Gottardi D, Hu H, Ricca I, De Crescenzo A, Tarella C
  Efficacy of rituximab-bendamustine in cold agglutinin haemolytic anaemia refractory to previous chemo-immunotherapy: a case report. Blood Transfus. 2013 Apr;11(2):311-4. doi: 10.2450/2012.0166-12.
•   Michel M
  Classification and therapeutic approaches in autoimmune hemolytic anemia: an update. Expert Rev Hematol. 2011 Dec;4(6):607-18. doi: 10.1586/EHM.11.60. Review.
•   Randen U, Trøen G, Tierens A, Steen C, Warsame A, Beiske K, Tjønnfjord GE, Berentsen S, Delabie J
  Primary cold agglutinin-associated lymphoproliferative disease: a B-cell lymphoma of the bone marrow distinct from lymphoplasmacytic lymphoma. Haematologica. 2014 Mar;99(3):497-504. doi: 10.3324/haematol.2013.091702.
•   Rummel M, Kaiser U, Balser C, Stauch M, Brugger W, Welslau M, Niederle N, Losem C, Boeck HP, Weidmann E, von Gruenhagen U, Mueller L, Sandherr M, Hahn L, Vereshchagina J, Kauff F, Blau W, Hinke A, Barth J; Study Group Indolent Lymphomas
  . Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial. Lancet Oncol. 2016 Jan;17(1):57-66. doi: 10.1016/S1470-2045(15)00447-7. Erratum in: Lancet Oncol. 2016 Jan;17(1):e6.
•   Schöllkopf C, Kjeldsen L, Bjerrum OW, Mourits-Andersen HT, Nielsen JL, Christensen BE, Jensen BA, Pedersen BB, Taaning EB, Klausen TW, Birgens H
  Rituximab in chronic cold agglutinin disease: a prospective study of 20 patients. Leuk Lymphoma. 2006 Feb;47(2):253-60.
•   Stone MJ
  Heating up cold agglutinins. Blood. 2010 Oct 28;116(17):3119-20. doi: 10.1182/blood-2010-07-297523.
•   Swiecicki PL, Hegerova LT, Gertz MA
  Cold agglutinin disease. Blood. 2013 Aug 15;122(7):1114-21. doi: 10.1182/blood-2013-02-474437. Review.
•   Ulvestad E, Berentsen S, Bø K, Shammas FV
  Clinical immunology of chronic cold agglutinin disease. Eur J Haematol. 1999 Oct;63(4):259-66.
•   Ulvestad E, Berentsen S, Mollnes TE
  Acute phase haemolysis in chronic cold agglutinin disease. Scand J Immunol. 2001 Jul-Aug;54(1-2):239-42.

The CAD5 Study::Therapy for Chronic Cold Agglutinin Disease: A Prospective, Non-randomized International Multicenter Trial on the Safety and Efficacy of Bendamustine and Rituximab Combination Therapy

Details for clinical trial NCT02689986